

Claims:

1. An RNAi agent for inhibiting expression of a Receptor for Advanced Glycation End-products gene, comprising:
 - an antisense strand comprising at least 17 contiguous nucleotides differing by 0 or 1 nucleotides from the sequence_UGAUGUUUUGAGCACCUACUC (SEQ ID NO:9) (5' → 3'); and
 - a sense strand comprising a nucleotide sequence that is at least partially complementary to the antisense strand.
2. The RNAi agent of claim 1, wherein at least one nucleotide of the RNAi agent is a modified nucleotide or includes a modified internucleoside linkage.
3. The RNAi agent of any one of claims 1-2, wherein all or substantially all of the nucleotides are modified nucleotides.
4. The RNAi agent of any one of claims 2-3, wherein the modified nucleotide is selected from the group consisting of: 2'-O-methyl nucleotide, 2'-fluoro nucleotide, 2'-deoxy nucleotide, 2',3'-seco nucleotide mimic, locked nucleotide, 2'-F-arabino nucleotide, 2'-methoxyethyl nucleotide, abasic nucleotide, ribitol, inverted nucleotide, inverted 2'-O-methyl nucleotide, inverted 2'-deoxy nucleotide, 2'-amino-modified nucleotide, 2'-alkyl-modified nucleotide, morpholino nucleotide, vinyl phosphonate-containing nucleotide, cyclopropyl phosphonate-containing nucleotide, and 3'-O-methyl nucleotide.
5. The RNAi agent of claim 3, wherein all or substantially all of the nucleotides are modified with 2'-O-methyl nucleotides, 2'-fluoro nucleotides, or combinations thereof.
6. The RNAi agent of claim 1, wherein the sense strand and the antisense strand are each 21 nucleotides in length.
7. The RNAi agent of any one of claims 1-6, wherein the sense strand comprises one or two terminal caps.
8. The RNAi agent of any one of claims 1-7, wherein the sense strand comprises one or two inverted abasic residues.
9. The RNAi agent of claim 1, wherein the sense strand consists of, consists essentially of, or comprises a nucleotide sequence that differs by 0 or 1 nucleotides from one of the following nucleotide sequences (5' → 3'):
GAGUAGGUGCUAAAACAUCA (SEQ ID NO:20).

10. The RNAi agent of claim 9, wherein all or substantially all of the nucleotides are modified nucleotides.
11. The RNAi agent of claim 1, comprising an antisense strand that comprises, consists of, or consists essentially of a modified nucleotide sequence that differs by 0 or 1 nucleotides from one of the following nucleotide sequences (5' → 3'):
usGfsasuguuuugaGfcAfcCfuacusc (SEQ ID NO:5); or
cPrpusGfsasuguuuugaGfcAfcCfuacusc (SEQ ID NO:6);



wherein a represents 2'-O-methyl adenosine, c represents 2'-O-methyl cytidine, g represents 2'-O-methyl guanosine, u represents 2'-O-methyl uridine; Af represents 2'-fluoro adenosine, Cf represents 2'-fluoro cytidine, Gf represents 2'-fluoro guanosine; cPrpu represents 5'-cyclopropyl phosphonate-2'-O-methyl uridine; s represents a phosphorothioate linkage; and wherein all or substantially all of the nucleotides on the sense strand are modified nucleotides.

12. The RNAi agent of claim 1, wherein the sense strand comprises, consists of, or consists essentially of a modified nucleotide sequence that differs by 0 or 1 nucleotides from the following nucleotide sequences (5' → 3'):
gsaguagGfuGfcUfcaaaacauca (SEQ ID NO:14);

wherein a represents 2'-O-methyl adenosine, c represents 2'-O-methyl cytidine, g represents 2'-O-methyl guanosine, u represents 2'-O-methyl uridine; Gf represents 2'-fluoro guanosine, Uf represents 2'-fluoro uridine; and s represents a phosphorothioate linkage; and wherein all or substantially all of the nucleotides on the antisense strand are modified nucleotides.

13. The RNAi agent of any one of claims 9-12, wherein the sense strand further includes inverted abasic residues at the 3' terminal end of the nucleotide sequence, at the 5' end of the nucleotide sequence, or at both.
14. The RNAi agent of any one of claims 1-13, wherein the RNAi agent is linked to a targeting ligand.

- or a pharmaceutically acceptable salt thereof, or




17. The RNAi agent of any one of claims 14-16, wherein the targeting ligand is conjugated to the sense strand.
18. The RNAi agent of claim 17, wherein the targeting ligand is conjugated to the 5' terminal end of the sense strand.
19. The RNAi agent of any of the preceding claims, wherein the RNAi agent is conjugated to a targeting ligand and has the duplex structure of AC001267, wherein AC001267 comprises the antisense strand of the nucleotide sequence (5' → 3'):

cPrpusGfsasuguuuugaGfcAfcCfuacusc (SEQ ID NO: 6) and the sense strand of the nucleotide sequence (5' → 3'):

Tri-SM6.1- α v β 6-(TA14)gsaguagGfuGfcUfcaaaacaucas(invAb) (SEQ ID NO: 11),

wherein a represents 2'-O-methyl adenosine, c represents 2'-O-methyl cytidine, g represents 2'-O-methyl guanosine, u represents 2'-O-methyl uridine; Af represents 2'-fluoro adenosine, Cf represents 2'-fluoro cytidine, Gf represents 2'-fluoro guanosine, Uf represents 2'-fluoro uridine; and s represents a phosphorothioate linkage; invAb represents an inverted abasic deoxyribonucleotide; and Tri-SM6.1- α v β 6-(TA14) represents the following structure:



20. A composition comprising the RNAi agent of any one of claims 1-19, wherein the composition further comprises a pharmaceutically acceptable excipient.

21. The composition of claim 20, further comprising a second RNAi agent capable of inhibiting the expression of Receptor for Advanced Glycation End-products gene expression.
22. The composition of any one of claims 20-21, further comprising one or more additional therapeutics.
23. The composition of any of claims 20-22, wherein the RNAi agent is a sodium salt.
24. The composition of any of claims 20-23, wherein the pharmaceutically acceptable excipient is a buffered saline solution.
25. Use of the composition according to any one of claims 20-24, for the manufacture of a medicament for treatment of a disease, disorder, or symptom that is mediated at least in part by Receptor for Advanced Glycation End-products receptor activity and/or Receptor for Advanced Glycation End-products gene expression.
26. The use of claim 25, wherein the disease is pulmonary inflammation.